Trial Profile
An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Lomvastomig (Primary)
- Indications Adenosquamous carcinoma; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Roche
- 22 Sep 2023 Planned End Date changed from 31 Aug 2023 to 30 Apr 2024.
- 22 Sep 2023 Planned primary completion date changed from 31 Aug 2023 to 30 Apr 2024.
- 23 Jan 2023 Planned End Date changed from 11 Feb 2023 to 31 Aug 2023.